Skip Ribbon Commands
Skip to main content

Study Summaries

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   |   Reference Center   |   Patient Resources   |   Study Summaries
  • Print
  • Share

Study Summaries for Patients

To increase the comprehension and usefulness of research studies for patients, the CIBMTR Consumer Advocacy Committee provides patient-level summaries of CIBMTR research articles. 


2017 Summaries


Summary (PDF) ​Important Points ​Full Article
Some children who donate cells to a brother or a sister have a lower quality of life and need extra support

About 20% of donors (1 in 5) at each time point had very poor QOL.

Parents tended to overestimate their child's QOL.

Younger children were more likely to have a lower QOL.

Health-related quality of life among pediatric hematopoietic stem cell donors.



2016 Summaries


Summary (PDF) ​Important Points ​Full Article
Transplant from half-matched donors may be as good as matched donors for people with lymphoma

​People were just as likely to be alive 3 years after transplant whether they had a matched sibling transplant or a haploidentical transplant.

Fewer people got GVHD after a haploidentical transplant.

​Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-mathced sibling donors: A Center for International Blood and Marrow Transplant Research analysis.
More older people with non-Hodgkin lymphoma get transplant Transplant is a treatment option for healthy older people with NHL Allogeneic hematopoietic cell tansplantation as curative therapy for patients with non-Hodgkin lymphoma: Inceasingly successful application to older patients.
Transplant may be better when it uses bone marrow compared to peripheral blood stem cells from unrelated donors ​At 5 years after transplant from an unrelated conor, people who got bone marrow had better quality of life than people who got PBSC. People who got bone marrow:
  • Were more likely to be back at work.
  • Said they felt better emotionally.
  • Had fewer symptoms of chronic GVHD.
Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: Long-term follow-up of a randomized clinical trial.
Transplant often affects family finances

At 2 years after transplant:

Most patients and caregivers thought transplant affected their family finances a medium or large amount.

Half of patients who worked before transplant were back to work.

Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: Results from a multicenter pilot study
Younger adults with high risk multiple myeloma may benefit from allo transplant

​Allo transplant may help people with high risk myeloma or myeloma that comes back early after an auto transplant live longer without the disease.

Younger people and people with no myeloma signs or symptoms before allo transplant lived longer without the disease.

Allogeneic hematopoietic cell tansplantation in multiple myeloma: Impact of disease risk and post allograft minimal residual disease on survival.
Comparing 2 types of blood and marrow transplant (BMT): Double cord blood and haplo-cord For both types of transplant, about half of patients were alive 1 year after transplant.

Patients who had a haplo-cord transplant had less GVHD, and the disease came back less often.
Reduced intensity haplo plus single cord transplant compared to double cord tranplant: Improved engraftment and survival free of progression and GVHD (GRFS).
​​Transplant outcomes for children and young adults with chronic myeloid leukemia (CML) ​Transplant outcomes are similar in children and young adults with CML.
Transplant works better with bone marrow from sibling donors.
Taking TKIs before transplant doesn't affect how well transplant works.
​​Outcomes of allogeneic hematopoietic cell transplantation in children (<18y) and young adults (18-29y) with chronic myeloid leukemia: A CIBMTR cohort analysis.
How to decide whether a child can safely donate blood-forming cells to a family member ​Experts make recommendations to help doctors and parents protect children who might donate blood-forming cells to a sick family member. ​​Determination of eligibility in related pediatric hematopoietic cell donors: ethical and clinical considerations. Recommendations from a working group of the Worldwide Network for Blood and Marrow Transplantation Association.
A survey that asks patients about their physical health before transplant may predict how they’ll do after transplant How patients feel physically before and after transplant affects transplant outcomes.


Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).
Transplant may help older patients with acute myeloid leukemia Reduced-intensity transplant is a good treatment option for some older patients with AML.


Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Younger unrelated donors are better for transplant patients The best unrelated donors are aged 18-32 years old and closely HLA-matched to the patient.


The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
Half-matched (haploidentical) transplant for patients with lymphoma Patients who had a haploidentical or unrelated donor transplant had about the same 3-year survival.

Patients who had a haploidentical transplant had less chronic GVHD.

Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors.
Experts develop transplant guidelines These recommendations are important guides for doctors and patients as they talk about whether BMT is a treatment option. ​Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.

2015 Summaries


Summary (PDF) ​Important Points ​Full Article
Patients with Relapsed / Refractory Follicular Lymphoma may Benefit from a Reduced-Intensity Allogeneic Transplant Auto transplant or reduced-intensity allo transplant can help patients with follicular lymphoma.

More than 2 years after transplant, patients who get an allo transplant are more likely to survive than patients who get an auto transplant.

​Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors.
Individualized Care Plans for Transplant Recipients: An Example of Patient-Centered Research ​Patients are involved in every step of the research process.

Researchers think the care plans will help patients be healthier and less stressed after transplant.

​Patient centeredness and engagement in quality-of-care oncology research.
National Survey of Transplant Center Resources, Staff, and Structure ​Different transplant centers have different resources, staff, and structure. National survey of hematopoietic cell transplantation center personnel, infrastructure, and models of care delivery.
Bone Marrow Donors have more Side Effects at Hospitals that do Fewer Bone Marrow Collections ​Bone marrow donors had more side effects at hospitals that did fewer bone marrow collections. An analysis of the effect of race, socioeconomic status and center size on unrelated NMDP donor outcomes: donor toxicities are more common at low volume bone marrow collection centers.
Transplant can help some Children with Hypodiploid Acute Lymphoblastic Leukemia Children with hypodiploid ALL did worse when they had a transplant later (in their 2nd complete remission).

Children with 43 or fewer chromosomes in their diseased cells had a higher risk of the leukemia coming back and dying after transplant compared to children with 44 or 45 chromosomes.

While more children may live longer because doctors can find better matched donors, disease factors still affect transplant outcomes.

Transplant outcomes for children with hypodiploid acute lymphoblastic leukemia.
A New way to Measure Acute Graft-Versus-Host Disease can Help Doctors Predict Transplant Outcomes The Refined Acute GVHD Risk Score is a way for doctors to predict the likelihood that:

A patient will be alive 6 months after starting treatment for acute GVHD.

Acute GVHD will get better with steroids.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
New Blood Test can Predict the Severity of Acute Graft-Versus-Host Disease ​Biomarkers can predict whether acute GVHD will be mild or severe and whether it is likely to respond to treatment. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
Patients with Myeloma or Lymphoma can have Excellent Outcomes After an Outpatient Autologous Transplant ​Outcomes (results) were similar in the inpatient and outpatient transplant groups. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
Allogeneic Transplant may be a Good Treatment Option for Patients 40 Years or Older with Non-Hodgkin Lymphoma Reduced-intensity transplant may help patients who are 40 years or older and have NHL.

The chance of getting GVHD did not depend on the patient's age.

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.  
Guidelines on Cancer Screening for Transplant Recipients​ Common places for new cancers after transplant are the mouth, skin, breast, and thyroid.

Both allogeneic and autologous transplant recipients have a higher chance of getting a new cancer.

Secondary solid cancer screening following hematopoietic cell transplantation.
Guidelines for Transplant and Multiple Myeloma ​Doctors should consider recommending an autologous transplant for most patients with multiple myeloma. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the ASBMT.
Fertility Preservation Options Before Transplant ​Tell your doctor right away if you want to talk about fertility preservation. Clinical guide to fertility preservation in hematopoietic cell transplant recipients.
Patients with Lymphoma have Similar Survival After Transplant Whether the Unrelated Donor is Matched, Mismatched, or Cord Blood ​3-year survival was about the same no matter what type of unrelated donor a patient had: matched, mismatched, or cord blood. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.
More Patients who have a Transplant from an Unrelated Donor Survive than in the Past ​3-year survival after transplant from an unrelated donor has increased over time. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era.
More Teens and Young Adults with ALL Survive After Blood or Marrow Transplant than in the Past 5-year survival increased over time in teens and young adults and in children. Survival improvements in adolescents and young adults after myeloblative allogeneic transplantation for acute lymphoblastic leukemia.


2014 Summaries


Summary (PDF) ​Important Points ​Full Article
Most Patients who Need an Allo Transplant Can Find a Well Matched Donor ​Most patients can find a well matched or a very well matched available adult donor in the Be The Match Registry.

Most patients can find a well matched cord blood unit that is big enough in the registry, but few patients can find a very well matched cord blood unit.

Almost all patients younger than 20 years old can find a well matched adult donor or cord blood unit.

It is important to find the best donor as soon as possible, so the transplant isn't delayed. If a very well matched donor isn't available, it is better to use a well matched donor than to wait to try to find a very well matched one.

HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
Very Few Donors have Severe Side Effects from Donation : Blood Stem Cell Donors have Fewer than Bone Marrow Donors Less than 1% of donors have severe side effects from donation.

Bone marrow donors have severe side effects 3 times more often than blood stem cell donors.

Blood stem cell donors who get G-CSF do NOT get cancer, an autoimmune illness, or a stroke more often than those who don't get G-CSF.

Lower risk of serious adverse events and no increased risk of cancer after PBSC versus bone marrow donation.
Allo Transplant Helps Some Older Patients with AML Older patients (aged 65 years and older) with AML can get high dose chemo if they are healthy enough.

About half of the older patients who get high dose chemo go into remission. However, the disease usually comes back within a year.

About 40% of older patients in remission who get an allo transplant live at least 2 years.

It is important for patients to talk with their doctor about an allo transplant as soon as they find out they have AML.

To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.​
Allo Transplant Helps Some Children with Neuroblastoma Only 4% of patients with neuroblastoma (NBL) get an allo transplant.

20% of patients with NBL who get an allo transplant go into remission for at least 5 years.

Patients with NBL who only get an allo transplant do better than patients who get an auto transplant first and then an allo transplant.

Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.


2013 Summaries 


Summary (PDF) ​Important Points ​Full Article
Older Sibling Donors are Better than Younger, Unrelated Donors for Older Patients ​An older sibling donor is better than a younger, unrelated donor for patients who are 50 or older.

Looking at patients with a high performance score (healthier patients):  patients with older sibling donors survive longer, relapse less, and get less GVHD than patients with younger, unrelated volunteer donors.
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
Doctors Surveyed about Talking to Patients about Fertility ​Hematopoietic cell transplantation can cause patients to become infertile. However, there are options for fertility preservation, which allow patients to have children in the future.

Most doctors who responded to the survey feel comfortable talking with patients about fertility preservation.

Patients must tell their doctor if they want to talk about fertility preservation.
Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients
Younger Sibling Donors Better for Children and Teens Needing Transplants ​Children and teen patients who get transplants from their younger siblings get less GVHD than patients who get transplants from their older siblings.

For adult patients, it makes no difference if a sibling donor is younger or older.
Birth order and transplantation outcome in HLA-identical sibling stem cell transplantations: an analysis on behalf of the Center for International Blood and Marrow Transplantation
Allo Transplant Helps Some Patients with DLBCL and Follicular Lymphoma when Chemotherapy and Radiation Don't ​25% of patients with either diffuse large B cell lymphoma (DLBCL) or grade 3 follicular lymphoma achieved durable remission after an allo transplant when chemotherapy and radiation alone didn't work.

Patients are just as likely to survive after transplant with a low dose of chemotherapy and radiation before transplant as with a high dose.

Patients have fewer serious side effects from a low dose of chemotherapy and radiation.
Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma
Allo Transplant Helps Some Patients with Mantle Cell Lymphoma when Chemotherapy and Radiation Don't ​25% of patients with mantle cell lymphoma went into remission after an allo transplant when chemotherapy and radiation alone didn't work.

Patients can do just as well after transplant with a low dose of chemotherapy and radiation as they would with a high dose.

Patients have fewer serious side effects from a low dose of chemotherapy and radiation.
Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research
SNPs - New Information for Matching Patients and Donors for Transplant ​Many complications of HLA-mismatched transplantation are the result of genes that are not currently tested in the pre-transplant evaluation process of donors and patients.

Scientists use SNPs, which are very small changes in the DNA genetic code, to locate unknown genes.

Some SNPs are associated with better results after transplantation than other SNPs.
Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation
Second Transplant Helpful for Myeloma Relapse ​25% of myeloma patients whose cancer returned after their first transplant went into a complete remission after a second transplant.

Patients who were in remission for at least 1.5 years after their first transplant lived almost twice as long after their second transplant as patients who relapsed in less than 1.5 years.

Salvage second hematopoietic cell transplantation in myeloma



Summaries Prior to 2013
Similar survival for leukemia patients receiving transplants from related vs. unrelated donors Summary (PDF) Full Article
Medical guidelines for survivors of stem cell transplantation Summary (PDF) Full Article
Outcomes of non-Hodgkin lymphoma patients receiving transplantations from related vs. unrelated donors Summary (PDF) Full Article
Cytogenetics classifications for leukemia patients undergoing transplantation Summary (PDF) Full Article
Long-term survival after transplantation Summary (PDF) Full Article
Risk score for chronic graft-versus-host disease (GVHD) Summary (PDF) Full Article
Statistical method for clustered time-to-event data Summary (PDF) Full Article
Cellular therapy studies in the Blood and Marrow Transplant Clinical Trials Network Summary (PDF) Full Article
Umbilical cord blood as transplantation graft source for adults with acute leukemia Summary (PDF) Full Article
Spouses, partners share mental distress of cancer and transplant Summary (PDF) Full Article
Stem Cell Transplantation "Vital Option" for Sickle Cell Patients Summary (PDF) Full Article
Unrelated umbilical cord blood transplants equal to unrelated bone marrow in helping children with acute leukemia Summary (PDF) Full Article
​​​Improving health for long-term survivors of cancer and transplants ​Summary (PDF) Full Article
​A quicker transplant with the best donor available is often the better choice Summary (PDF) ​Full Article
Access to bone marrow and stem cell transplant differs among different groups Summary (PDF) Full Article #1
Full Article #2

To view PDF documents you will need Adobe Reader.
Get Adobe Reader




Access U.S. Transplant and Survival Statistics
Last Updated: 2/7/2017 2:19 PM